FDA Approval: Cetuximab (Erbitux) for Colorectal Cancer

The approval, in one paragraph

On February 12, 2004, the Food and Drug Administration approved Erbitux, the brand name for cetuximab, under Biologic License Application 125084, filed by ImClone. Two uses were approved at once: cetuximab with the chemotherapy drug irinotecan, for people whose metastatic colorectal cancer had stopped responding to irinotecan-based chemotherapy; and cetuximab on its own, for people who could not tolerate irinotecan-based chemotherapy.

Both were limited to tumors that expressed EGFR, the epidermal growth factor receptor.

What EGFR is and why blocking it matters

EGFR is a protein that sits on the surface of many cells. When a growth signal binds to it, the receptor tells the cell to divide. In some cancers that switch is stuck on, or is being pushed far harder than normal.

Cetuximab is a monoclonal antibody, a laboratory-made protein designed to lock onto one target. It binds to the outside part of EGFR and blocks the signal. It is a chimeric antibody, part mouse and part human, which matters later in this story.

That mechanism puts it in the family our guide to targeted therapy describes: drugs aimed at a specific molecule inside or on a cancer cell, rather than at fast-dividing cells generally.

What the evidence actually showed

Metastatic colorectal cancer is the setting here. The American Cancer Society projects 158,850 new colorectal cancers in the United States in 2026 and 55,230 deaths, and SEER, the federal cancer statistics program, publishes those. About 23 percent have already spread to distant sites when they are found.

The main study was a multicenter randomized controlled trial in 329 people whose metastatic colorectal cancer had progressed after irinotecan. Of those, 218 received cetuximab plus irinotecan and 111 received cetuximab alone. An independent radiology committee, blinded to which treatment people had received, judged the results.

The measure was objective response rate: the proportion of people whose tumors shrank by a defined amount on scans. In the combination arm it was 22.9 percent. With cetuximab alone it was 10.8 percent. The difference was 12.1 percentage points, with a 95 percent confidence interval of 4.1 to 20.2 and a p-value of 0.007.

Responses did not last long. The median duration was 5.7 months in the combination arm and 4.2 months with cetuximab alone.

The sentence in the label that matters most

FDA labels are not marketing documents, and the 2004 Erbitux label said this outright: "The effectiveness of ERBITUX is based on objective response rates. Currently, no data are available that demonstrate an improvement in disease-related symptoms or increased survival with ERBITUX."

That is unusually direct. Tumor shrinkage on a scan is a surrogate endpoint, meaning a stand-in for the outcome people actually care about. Sometimes shrinkage tracks living longer or feeling better. Sometimes it does not. At approval, that link had not been shown for this drug.

The side effect that led the label

Cetuximab carried a boxed warning from day one. Severe infusion reactions occurred in about 3 percent of people, and rarely were fatal, in fewer than 1 in 1,000. About 90 percent of severe reactions came with the very first infusion.

The label describes them as a rapid onset of airway obstruction, with wheeze, harsh breathing or hoarseness, along with hives and a drop in blood pressure. The instruction is immediate: stop the infusion and never restart the drug. This is one reason first doses are given where staff and equipment for that emergency are on hand.

What this approval cannot tell you

• It does not show that cetuximab helped people live longer. FDA said so in the label itself.
• Response rates in a trial describe a selected group. Everyone in this study had already progressed on irinotecan and had EGFR-expressing tumors confirmed by a laboratory test.
• It says nothing about first-line treatment, earlier-stage colorectal cancer, or any other cancer.
• Labels change. This one has been revised many times since 2004 as more evidence arrived, and current eligibility is not the same as 2004 eligibility.

That last point deserves emphasis. The 2004 label required EGFR expression, and the label noted that response did not correlate with either the percentage of cells expressing EGFR or the strength of that expression. Later research reshaped who receives this drug, and modern testing looks at genes such as KRAS instead. Our page on biomarker testing explains how those tests work.

How to read any approval like this one

An approval is a regulator's judgment that evidence met a bar for one specific use. It is not a statement that a drug works for everyone with that cancer, and it is not a promise of benefit.

Three questions get you most of the way:

• What exactly was approved? Read the indication, not the headline. Here it was a particular line of treatment, after a particular drug had failed, in tumors with a particular protein.
• What was measured? Response rate, progression-free survival and overall survival answer different questions.
• What is the comparison? A trial with no untreated comparison group cannot tell you how much of the effect came from the drug.

Our guides to clinical trial phases and targeted therapy go further into both.

Sources

• https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/125084lbl.pdf
• https://www.cancer.gov/about-cancer/treatment/drugs/cetuximab
• https://www.cancer.gov/types/colorectal
• https://seer.cancer.gov/statfacts/html/colorect.html

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.